机译:双特异性抗体的临床型展开,安全有效地靶向CD19和CD47,用于治疗B细胞淋巴瘤和白血病
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Univ Geneva Fac Med Geneva Switzerland;
Univ Geneva Fac Med Geneva Switzerland;
Rennes 1 Univ INSERM U1236 Rennes France;
Rennes 1 Univ INSERM U1236 Rennes France;
Rennes 1 Univ INSERM U1236 Rennes France;
Josep Carreras Leukaemia Res Inst IJC Campus ICO Germans Trias Pujol Barcelona Spain;
Josep Carreras Leukaemia Res Inst IJC Campus ICO Germans Trias Pujol Barcelona Spain;
Josep Carreras Leukaemia Res Inst IJC Campus ICO Germans Trias Pujol Barcelona Spain;
UCL Inst Canc Paul OGorman Bldg London England;
UCL Inst Canc Paul OGorman Bldg London England;
UCL Inst Canc Paul OGorman Bldg London England;
Washington Univ Sch Med Div Oncol St Louis MO USA;
Washington Univ Sch Med Div Oncol St Louis MO USA;
Washington Univ Sch Med Div Oncol St Louis MO USA;
Washington Univ Sch Med Div Oncol St Louis MO USA;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
Novimmune SA 14 Chemin Aulx CH-1228 Plan Les Ouates Switzerland;
机译:双特异性抗体的临床型展开,安全有效地靶向CD19和CD47,用于治疗B细胞淋巴瘤和白血病
机译:双特异性T细胞参录(咬合)抗体Blinatumab用于治疗复发/难治性急性淋巴细胞白血病和非霍奇金淋巴瘤的疗效和安全性:全身评测和荟萃分析
机译:双特异性T细胞参与者(咬合)抗体Blinatumab用于治疗复发/难治急性淋巴细胞白血病和非霍奇金淋巴瘤的疗效和安全性:系统性评论和荟萃分析
机译:靶向CD22 + B-白血病或淋巴瘤的双特化学自组装抗体纳米(CSAN)T细胞啮合的设计与表征
机译:人CD19 / CD3双特异性T细胞衔接子(BiTERTM)抗体blinatumomab与杂种鼠替代CD19 / CD3 BiTE抗体hyS103的比较药理学。
机译:临床上安全有效地靶向CD19和CD47的双特异性抗体可用于治疗B细胞淋巴瘤和白血病
机译:用针对CD19和CD5的工程化双特异性抗体免疫治疗B细胞淋巴瘤